Legend Biotech
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
77 Corporate Dr Fl 4, Bridgewater, New J...Phone Number
(732) 515-4652Website
www.legendbiotech.comRevenue
$1.1 BillionStock Symbol
LEGNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications.Explore more
Legend Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Legend Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Legend Biotech launches new products
Check out if Legend Biotech is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Legend Biotech recently announced quarterly report
Funding: Get notified immidiatlly once Legend Biotech has new funding data
Check if Legend Biotech has recently received funding, and reach out quickly before it becomes old news!
Legend Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Legend Biotech had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Legend Biotech
Recommended Actions
Find VP level buyers at Legend Biotech
Find 3 more new buyers
Company Profile Activity
Activity Insights
Legend Biotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Legend Biotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Legend Biotech.
Legend Biotech financials insights
Gather financial insights about Legend Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$150.5M
Stock Offering
$424M
Legend Biotech Tech Stack
A closer look at the technologies used by Legend Biotech
See more technologies
Most Recent Scoops
Open Position
Project
Legend Biotech has reported additional CARTITUDE-4 program data supporting the durable efficacy and consistent safety profile of CARVYKTI in multiple myeloma, including a sustained progression-free and overall survival benefit across cytogenetic risk groups and a low incidence of immune effector cell-associated enterocolitis, with patients who responded to bridging therapy demonstrating 30-month overall survival rates exceeding 85%.
Medical Research, Pharmaceuticals
Project
Legend Biotech has reported that LB2102, its DLL3-targeted CAR T therapy being evaluated in small cell lung cancer and large cell neuroendocrine carcinoma, demonstrated a manageable safety profile and encouraging clinical activity in a heavily pretreated patient population, with higher dose levels achieving an objective response rate of 28.6% and a disease control rate of 78.6%, with durable responses observed.
Medical Research, Pharmaceuticals
Earnings
Legend Biotech has reported an income tax expense of $22.3 million for Q2 2026, compared with approximately $600,000 for the same quarter last year, driven by increased taxable income across its US, Belgium, and PRC entities, and anticipates a tax rate in the high 20% range over the next several quarters.
Finance, Tax
Earnings
Business Finance, Finance, Financial Transactions, Financing & Debt
Legend Biotech News & Media
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call August 11, 2026 8:00 AM EDTCompany ParticipantsCaroline LeCates PaulAlan Bash - Interim CEO &...Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Shares of Legend Biotech (NASDAQ:LEGN) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first quarter of company-wide profitability in its history. LEGN stock is still down 41% over the past year, so today’s reaction reads as validation of Legend Biotech’s CARVYKTI ... Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles ConsensusLegend Biotech Q2 Earnings Call Highlights
Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company’s first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call. Interim Chief Executive Officer Alan Bash saidLegend Biotech Reports Second Quarter 2026 Results and Recent Highlights
BRIDGEWATER, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2026 unaudited financial results and key corporate highlights.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Legend Biotech
Sign Up For FreeTo access detailed company insights
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications.... Read More
